Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer

Patent metadata

Field	Value
Publication number	US-10378058-B2
Application number	US-94364410-A
Country	US
Kind code	B2
Filing date	Nov 10, 2010
Priority date	Nov 5, 2003
Publication date	Aug 13, 2019
Grant date	Aug 13, 2019

Abstract

Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.

First claim

What is claimed is:

1. A method for administering a treatment regimen comprising an effective amount of a P13K inhibitor, said method comprising:
(1) assaying a patient sample comprising at least one test cancer cell to measure the amount of PTEN protein having the amino acid sequence of SEQ ID NO:2 using at least one technique chosen from the group consisting of immunohistochemistry, immunoprecipitation, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoradiometric assay, fluoroimmunoassay, chemiluminescent assay, bioluminescent assay, western blot, antibody array, and FACS analysis;
(2) comparing the amount of PTEN protein measured in (1) to a reference amount of PTEN protein in reference cancer cells of a reference cohort of patients who are not candidates for said treatment regimen; and
(3) administering said treatment regimen to a test patient for whom said at least one test cancer cell is measured in (1) to have an absence of detectable PTEN protein or an amount of PTEN protein that is no more than 50% of said reference amount of PTEN protein in (2).

2. The method of claim 1 , wherein said at least one test cancer cell is selected from the group consisting of breast cancer cells, lung cancer cells, ovarian cancer cells, brain cancer cells, gastrointestinal tract cancer cells, salivary duct cancer cells, endometrial cancer cells, prostate cancer cells, head & neck cancer cells, glioma cells, pancreatic cancer cells, hepatocellular cancer cells, myeloma cells, soft tissue sarcoma cells, and non-small cell lung cancer cells.

3. The method of claim 1 , wherein said treatment regimen is administered to a test patient for whom said at least one test cancer cell is measured in (1) to have an absence of detectable PTEN protein or an amount of PTEN protein that is no more than 80% of said reference amount of PTEN protein in (2).

4. A method for administering a first treatment regimen comprising an effective amount of a PI3K inhibitor, said method comprising:
(1) assaying a patient sample comprising at least one test cancer cell to measure the amount of PTEN protein having the amino acid sequence of SEQ ID NO:2 using at least one technique chosen from the group consisting of immunohistochemistry, immunoprecipitation, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoradiometric assay, fluoroimmunoassay, chemiluminescent assay, bioluminescent assay, western blot, antibody array, and FACS analysis;
(2) comparing the amount of PTEN protein measured in (1) to a reference amount of PTEN protein in reference cancer cells of a reference cohort of patients who are not candidates for said first treatment regimen; and
(3) (a) administering said first treatment regimen to a test patient for whom said at least one test cancer cell is measured in (1) to have an absence of detectable PTEN protein or an amount of PTEN protein that is no more than 50% of said reference amount of PTEN protein in (2); or
(3) (b) administering a second treatment regimen comprising trastuzumab to a test patient for whom said at least one test cancer cell is measured in (1) to have an amount of PTEN protein that is greater than 50% of said reference amount of PTEN protein in (2).

5. The method of claim 4 , wherein said at least one test cancer cell is selected from the group consisting of breast cancer cells, lung cancer cells, ovarian cancer cells, brain cancer cells, gastrointestinal tract cancer cells, salivary duct cancer cells, endometrial cancer cells, prostate cancer cells, head & neck cancer cells, glioma cells, pancreatic cancer cells, hepatocellular cancer cells, myeloma cells, soft tissue sarcoma cells, and non-small cell lung cancer cells.

6. The method of claim 4 , wherein in (3)(a) said first treatment regimen is administered to a test patient for whom said at least one test cancer cell is measured in (1) to have an absence of detectable PTEN protein or an amount of PTEN protein that is no more than 80% of said reference amount of PTEN protein in (2); and in (3)(b) said second treatment regimen is administered to a test patient for whom said at least one test cancer cell is measured in (1) to have an amount of PTEN protein that is greater than 80% of said reference amount of PTEN protein in (2).

Assignees

• Yu Dihua
• Zhou Xiaoyan
• Nagata Yoichi
• Esteva Francisco J
• Sahin Aysegul A
• Univ Texas

Inventors

• Yu Dihua
• Zhou Xiaoyan
• Nagata Yoichi
• Esteva Francisco J
• Sahin Aysegul A

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/57515

  of the breast · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• Y10T436/25

  including sample preparation · CPC title

• G01N33/5011

  for testing antineoplastic activity · CPC title